Technological projects portfolio
X-OXAZA
Oxazaphosphorine prodrug with improved therapeutic index for the treatment of cancers
Investment: €519k
Scope: Healthcare
Scientific field(s): Biology and medicinal chemistry
Institution(s): Institut Gustave Roussy – INSERM
Development: Technology to be marketed
USE CASES
Ifosfamide is an old alkylating agent that remains one of the main cytotoxic drugs for sarcoma, in particular rhabdomyosarcoma in children.
Its use is limited due to the known neurotoxicity and nephrotoxicity of one of its metabolites, which limits optimal dosing.
The medical need is significant, and an improved, non-neurotoxic formulation of ifosfamide would provide a more effective therapeutic solution in conventional chemotherapy.
ADVANTAGES
The X-OXAZA project has developed a formulation using a nanoassembly of geranyloxy-ifosfamide and farnesyloxy-ifosfamide that improves the pharmacological characteristics of the active substance. The totality of the product is delivered in the form of an active alkylating agent.
APPLICATIONS
Due to the increased therapeutic index, the treatment of pediatric sarcoma is the primary target.
Other indications may be considered, notably those relating to immunogenic properties in combination with immune checkpoints.
